IL2 and type 1 diabetes mellitus: To gain further insight into the mechanism of action of iLD-IL-2, we selected 18 DILfrequency participants (adults with long-standing T1D) treated with this dosing regimen (Supplementary Data 1) and characterised the cellular alterations in blood by polychromatic flow-cytometry (FACS).